Humacyte

Yahoo Finance • 16 hours ago

Sector Update: Health Care Stocks Decline Monday Afternoon

Health care stocks were lower Monday afternoon, with the NYSE Health Care Index shedding 0.9% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 18 hours ago

Humacyte jumps as U.S. legislation backs bioengineered vessels

[Capitol Building Sunset - Washington DC] Douglas Rissing Humacyte (HUMA [https://seekingalpha.com/symbol/HUMA]) added ~27% on Monday after the Durham, North Carolina-based biotech said that the U.S. Congress has passed legislation provid... Full story

Yahoo Finance • 22 hours ago

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that th... Full story

Yahoo Finance • 2 months ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - -... Full story

Yahoo Finance • 2 months ago

Humacyte announces credit facility of $77.5M with Avenue Capital

* Humacyte (HUMA [https://seekingalpha.com/symbol/HUMA]) said on Tuesday that it has entered into a credit facility [https://seekingalpha.com/pr/20340828-humacyte-announces-credit-facility-of-up-to-77_5-million-with-avenue-capital] with... Full story

Yahoo Finance • 3 months ago

Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise

Earnings Call Insights: Humacyte, Inc. (HUMA) Q3 2025 MANAGEMENT VIEW * Laura Niklason, Founder, President, CEO & Director, highlighted significant progress in the commercial launch of Symvess, reporting "product sales improved to $703... Full story

Yahoo Finance • 3 months ago

Strong Earnings and Biotech Resilience Define the Midweek Momentum

DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB: KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe... Full story

Yahoo Finance • 3 months ago

Humacyte, Inc. Q3 Loss Narrows

(RTTNews) - Humacyte, Inc. (HUMA) announced Loss for third quarter of -$17.51 million The company's bottom line totaled -$17.51 million, or -$0.11 per share. This compares with -$39.20 million, or -$0.33 per share, last year. Humacyte,... Full story

Yahoo Finance • 3 months ago

Humacyte GAAP EPS of -$0.11 beats by $0.05, revenue of $0.75M misses by $0.17M

* Humacyte press release [https://seekingalpha.com/pr/20303336-humacyte-announces-third-quarter-2025-financial-results-and-provides-business-update] (HUMA [https://seekingalpha.com/symbol/HUMA]): Q3 GAAP EPS of -$0.11 beats by $0.05. *... Full story

Yahoo Finance • 3 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial... Full story

Yahoo Finance • 4 months ago

Humacyte rises after positive data from humanitarian study of Symvess

[Doctor working in lab during COVID-19 outbreak] Morsa Images/DigitalVision via Getty Images Humacyte (NASDAQ:HUMA [https://seekingalpha.com/symbol/HUMA]) shares surged following the release of data from a humanitarian initiative that uti... Full story

Yahoo Finance • 4 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

- Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., Oct. 06, 2025 (G... Full story

Yahoo Finance • 5 months ago

Humacyte Plans To File IND For Coronary Tissue Engineered Vessel In Q4

(RTTNews) - Humacyte, Inc. (HUMA) on Thursday said it plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the fourth quarter for its coronary tissue engineered vessel (CTEV) in co... Full story

Yahoo Finance • 5 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained patent through six mon... Full story

Yahoo Finance • 5 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated... Full story

Yahoo Finance • 5 months ago

Humacyte files $350M mixed securities shelf

* Humacyte (NASDAQ:HUMA [https://seekingalpha.com/symbol/HUMA]) filed $350M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10414382] MORE ON HUMACYTE * Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Prog... Full story

Yahoo Finance • 5 months ago

Humacyte, Senseonics jump as Barclays issues new Overweight ratings

[Sign for Wall Street in New York City] Pharrel Wiliams Bioengineered tissue maker Humacyte (NASDAQ:HUMA [https://seekingalpha.com/symbol/HUMA]) and Senseonics (NYSE:SENS [https://seekingalpha.com/symbol/SENS]), a developer of continuous... Full story

Yahoo Finance • 6 months ago

Which stocks are experiencing notable movement on Monday?

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 77.82% Positive ma... Full story

Yahoo Finance • 6 months ago

Let's have a look at the top gainers and losers in the middle of the day of today's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 87.56% With a 87.56% surge... Full story

Yahoo Finance • 6 months ago

Monday's session: gap up and gap down stocks

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT ENTO [https://www.chartmill.com/stock/quote/ENTO/p... Full story